Efficacy and safety of generic daclatasvir + sofosbuvir ± ribavirin in treatment of genotype 3 infected hepatitis C patients - a real life experience from Pakistan

Abstract

Aim: Genotype 3 is the most prevalent genotype in Pakistan. Despite a revolution in the treatment of Hepatitis C, genotype 3 is still thought to be difficult to treat genotype. The price of patent direct acting antivirals was thought to a great limiting factor especially for low income countries. In Pakistan low cost generics of daclatasvir and sofosbuvir are easily available for treatment. The aim of our study is to provide real life local data to determine their efficacy and safety.

Methods: This open-label, non-randomized, uncontrolled study was carried out at Center for Liver and Digestive Diseases, Holyfamily Hospital, Rawalpindi. We enrolled patients from March 2016 through March 2018 who were 18 years or older having chronic hepatitis C infection with detectable polymerase chain reaction (PCR), regardless of whether they were treatment naïve or have experienced Interferon in the past. The patients were offered generic sofosbuvir 400 mg and daclatasvir 60 mg once daily with or without ribavirin for a period of 12 to 24 weeks. Follow-up PCRs were performed at 4th week of treatment, end of treatment and 12 weeks post treatment. All those patients were included in the study that had at least one follow-up PCR during or after the course of treatment.

Results: A total of 102 patients were enrolled in the study with a mean age of 48.11 ± 12.70 including 63% males and 37% females. All patients were genotype 3. On 4th week follow up, 31/36 (86.11%) patients had quantitative PCR negative. Out of 102 patients, 78 patients had follow up PCR at the completion of therapy with an end of treatment response of about 96.1%. Thirty patients had a follow up at 12 weeks post treatment with a SVR12 of 83.33% (25/30) amongst which treatment Naïve had a response rate of 84% (21/25), treatment experience 80% (4/5), non-cirrhotics 85.71% (12/14), cirrhotics 81.25% (13/16) and decompensated chronic liver disease patients have a SVR12 of about 83.33% (10/12) respectively. The combination was well tolerated with few side effects, 18.6% patients had itching, 10.8% had insomnia, 8.8% had oral ulcers and 6.9% had fatigue.

Conclusion: Generic sofosbuvir and daclatasvir are cheap, safe and efficacious with a SVR12 of about 83.33% amongst genotype 3 patients. These generics will act as a pivot in the eradication of hepatitis C infection from developing world.

Keywords

Daclatasvir / sofosbuvir / genotype 3 / hepatitis C

References

[1] Gower E,Blach S,Razavi H.Global epidemiology and genotype distribution of the hepatitis C virus infection..J Hepatol2014;61:45-57

[2] Umar M,Akhter TS,Ahmad SI.Diagnosis, management and prevention of hepatitis C in Pakistan 2017..J Ayub Med Coll Abbottabad2016;28:S839-82

[3] Sadler MD.Treatment of genotype 3 chronic hepatitis C virus infection..Clin Med Insights Ther2017;9:1-7

[4] Hill A,Gotham D.Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C..J Virus Erad2016;2:28-31 PMCID:PMC4946692

[5] Leroy V,Bronowicki JP,Hezode C.Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+)..Hepatology2016;63:1430-1 PMCID:PMC5069621

[6] Gamal N,Andreone P.Efficacy and safety of daclatasvir in hepatitis C: an Overview..J Clin Transl Hepatol2016;4:336-44 PMCID:PMC5225154

[7] National Assembly Secretariat (34th Session). Available from: http://www.na.gov.pk/uploads/documents/questions/1470057800_189.pdf. [Last accessed on 30 Oct 2018]

[8] Hill A.Hepatitis C can be cured globally, but at what cost?.Science2014;345:141-2

[9] Gilead Sciences Inc. Chronic hepatitis C treatment expansion: generic manufacturing for developing countries. 2015. Available from: http://www.gilead.com/~/media/Files/pdfs/other/HCVGenericAgreementFactSheet.pdf. [Last accessed on 30 Oct 2018]

[10] Welzel TM,Herzer K,Gschwantler M.Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort..Gut2016;65:1861-70 PMCID:PMC5099229

[11] World Health Organization. Prequalification of medicines by WHO. Available from: http://www.who.int/mediacentre/factsheets/fs278/en/. [Last accessed on 23 Oct 2018]

[12] Hill A,Mohammed MK,Khwairakpam G.Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals..J Virus Erad2018;4:e37-40

[13] Hajarizadeh B.Generic direct acting antiviral treatment: the first step towards elimination of hepatitis C in Iran..Hepat Mon2017;17:e45788

[14] Salama H,Medhat E,Shousha H.Sofosbuvir plus daclatasvir with fixed versus weight adjusted dose of ribavirin for treatment of HCV, genotype 4 among Egyptian patients..EC Gastroenterology and Digestive System2016;1:143-53

[15] Aggarwal R,Goel A,Pendse R.Cost-effectiveness of hepatitisC treatment using generic direct-acting antivirals available in India..PLoS One2017;12:e0176503 PMCID:PMC5435174